Jennison Associates’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Jennison Associates’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-15,945	Closed	-$909K	–	708
2017 Q2	$909K	Sell	15,945 -925	-5%	-$46.4K	﹤0.01%	586
2017 Q1	$907K	Hold	16,870	–	–	﹤0.01%	580
2016 Q4	$962K	Buy	+16,870	New	+$1.02M	﹤0.01%	614
2016 Q2	–	Sell	-176,346	Closed	-$11.3M	–	666
2016 Q1	$11.3M	Buy	176,346 +5,278	+3%	+$427K	0.01%	446
2015 Q4	$24.1M	Buy	171,068 +14,815	+9%	+$2.01M	0.02%	398
2015 Q3	$15.1M	Buy	156,253 +6,273	+4%	+$747K	0.02%	469
2015 Q2	$22.3M	Buy	+149,980	New	+$24.8M	0.02%	446

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates's KDNY Position: Q3 2017 in Review

Jennison Associates sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2017, closing a stake of 15,945 shares — an estimated $909K sold.

Jennison Associates first reported a position in KDNY in Q2 2015 and held it in 7 quarters. The position peaked at $24.1M in Q4 2015. 90 funds tracked by Wall St. Rank hold KDNY as of Q3 2017.

Jennison Associates reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Jennison Associates sold 15,945 Chinook Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $909K.
Jennison Associates first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 7 quarters.
Jennison Associates's Chinook Therapeutics, Inc. Common Stock position peaked at $24.1M in Q4 2015.
90 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Jennison Associates's 13F filing for Q3 2017, filed 3 Nov 2017.